Barclays lowered the firm’s price target on Syndax (SNDX) to $19 from $33 and keeps an Overweight rating on the shares as part of a Q1 earnings preview. The firm says that while difficult to call the quarter with “many moving parts and caveats of sampling error,” its survey of 25 doctors for Syndax’s Revuforj doesn’t point to a beat, but broadening use. Barclays de-risked the model “out of an abundance of caution in the current macro backdrop.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax participates in a conference call with JPMorgan
- Syndax price target raised to $41 from $39 at JPMorgan
- Strong Buy Rating for Syndax Pharmaceuticals Driven by Revuforj’s Market Potential and Revenue Growth
- Positive Outlook on Syndax Pharmaceuticals: Strong Market Presence and Strategic Growth Initiatives
- Syndax price target raised to $39 from $35 at JPMorgan